Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma

被引:38
作者
Fukui, Koji
Tamura, Shinji
Wada, Akira
Kamada, Yoshihiro
Sawai, Yoshiyuki
Imanaka, Kazuho
Kudara, Takahiko
Shimomura, Iichiro
Hayashi, Norio
机构
[1] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan
关键词
RhoA; hepatocellular carcinoma; recurrence;
D O I
10.1007/s00432-006-0107-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Rho sub-family of proteins is involved in regulating the organization of the cytoskeleton and in cell motility. Our aim is to clarify the clinical significance of Rho protein in hepatocellular carcinomas (HCC) and to determine the relationship between the level of expression and patient outcome following hepatectomy. The expression of RhoA protein in HCC and corresponding non-tumor tissues of 26 patients who underwent surgical resection was analyzed by immunoblotting. The expression level of each case was calculated as tumor/non-tumor (T/N) ratios. High expression (T/N >= 1) of RhoA protein in HCC compared to the paired non-tumor tissues was recognized in 18 patients (69.2%) of 26 samples. The activity of RhoA is also increased in HCC with high expression of RhoA. The high expression of RhoA protein did not correlate with various clinical parameters. However, the disease-free survival rates of the RhoA-high expression group (T/N >= 1) were significantly lower than those of the RhoA-low expression group (T/N<1) (P<0.05). The high expression of RhoA protein in HCC plays an important role in intrahepatic recurrence of patients who underwent a hepatectomy for HCC, and RhoA is a useful marker for predicting early recurrence in an early-stage HCC.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 29 条
[11]   An essential part for Rho-associated kinase in the transcellular invasion of tumor cells [J].
Itoh, K ;
Yoshioka, K ;
Akedo, H ;
Uehata, M ;
Ishizaki, T ;
Narumiya, S .
NATURE MEDICINE, 1999, 5 (02) :221-225
[12]  
Kamai T, 2003, CLIN CANCER RES, V9, P2632
[13]   Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial [J].
Kawata, S ;
Yamasaki, E ;
Nagase, T ;
Inui, Y ;
Ito, N ;
Matsuda, Y ;
Inada, M ;
Tamura, S ;
Noda, S ;
Imai, Y ;
Matsuzawa, Y .
BRITISH JOURNAL OF CANCER, 2001, 84 (07) :886-891
[14]   Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma [J].
Kumada, T ;
Nakano, S ;
Takeda, I ;
Sugiyama, K ;
Osada, T ;
Kiriyama, S ;
Sone, Y ;
Toyoda, H ;
Shimada, S ;
Takahashi, M ;
Sassa, T .
HEPATOLOGY, 1997, 25 (01) :87-92
[15]  
LANG P, 1992, J BIOL CHEM, V267, P11677
[16]   Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity [J].
Leung, THY ;
Ching, YP ;
Yam, JWP ;
Wong, CM ;
Yau, TO ;
Jin, DY ;
Ng, IOL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (42) :15207-15212
[17]   Rho: A connection between membrane receptor signalling and the cytoskeleton [J].
Machesky, LM ;
Hall, A .
TRENDS IN CELL BIOLOGY, 1996, 6 (08) :304-310
[18]   SURGERY FOR SMALL LIVER CANCERS [J].
MAKUUCHI, M ;
KOSUGE, T ;
TAKAYAMA, T ;
YAMAZAKI, S ;
KAKAZU, T ;
MIYAGAWA, S ;
KAWASAKI, S .
SEMINARS IN SURGICAL ONCOLOGY, 1993, 9 (04) :298-304
[19]   RHO-GENE PRODUCTS, BOTULINUM C3 EXOENZYME AND CELL-ADHESION [J].
NARUMIYA, S ;
MORII, N .
CELLULAR SIGNALLING, 1993, 5 (01) :9-19
[20]  
PERONA R, 1993, ONCOGENE, V8, P1285